Michael Weintraub Sells 15,177 Shares of Phreesia (NYSE:PHR) Stock

Phreesia (NYSE:PHR) Director Michael Weintraub sold 15,177 shares of the company’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $32.79, for a total transaction of $497,653.83. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Michael Weintraub also recently made the following trade(s):

  • On Wednesday, February 12th, Michael Weintraub sold 10,680 shares of Phreesia stock. The stock was sold at an average price of $32.51, for a total transaction of $347,206.80.

Shares of Phreesia stock opened at $32.61 on Friday. The company has a current ratio of 4.01, a quick ratio of 4.01 and a debt-to-equity ratio of 0.21. The company’s 50-day moving average price is $28.93 and its two-hundred day moving average price is $27.71. Phreesia has a 52 week low of $22.05 and a 52 week high of $34.39.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Tuesday, December 10th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03. The business had revenue of $32.80 million during the quarter, compared to the consensus estimate of $29.48 million. The company’s revenue was up 32.3% compared to the same quarter last year. As a group, analysts expect that Phreesia will post -0.43 earnings per share for the current fiscal year.

Several equities research analysts recently weighed in on the stock. ValuEngine downgraded shares of Phreesia from a “buy” rating to a “hold” rating in a report on Thursday, October 31st. Zacks Investment Research cut shares of Phreesia from a “buy” rating to a “hold” rating in a research report on Tuesday. Raymond James initiated coverage on shares of Phreesia in a research report on Thursday, December 19th. They issued an “outperform” rating and a $33.00 price target on the stock. KeyCorp initiated coverage on shares of Phreesia in a research report on Thursday, January 30th. They issued an “overweight” rating and a $36.00 price target on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of Phreesia in a research report on Wednesday, January 8th. They issued an “overweight” rating and a $32.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Phreesia presently has an average rating of “Buy” and a consensus target price of $31.78.

A number of institutional investors have recently modified their holdings of PHR. Altshuler Shaham Ltd acquired a new stake in Phreesia during the 4th quarter worth about $29,000. Bank of Montreal Can acquired a new stake in Phreesia during the 4th quarter worth about $33,000. Russell Investments Group Ltd. acquired a new stake in Phreesia during the 3rd quarter worth about $47,000. Victory Capital Management Inc. acquired a new stake in Phreesia during the 4th quarter worth about $53,000. Finally, Citigroup Inc. raised its holdings in Phreesia by 339.2% during the 4th quarter. Citigroup Inc. now owns 2,073 shares of the company’s stock worth $55,000 after buying an additional 1,601 shares during the period. Hedge funds and other institutional investors own 51.49% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.

Read More: Growth Stocks

Insider Buying and Selling by Quarter for Phreesia (NYSE:PHR)

Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.